Geary Richard S 4

Accession 0000874015-25-000277

CIK 0000874015other

View on SEC.gov Company Profile

Filed

Nov 6, 7:00 PM ET

Accepted

Nov 7, 5:12 PM ET

Size

24.3 KB

Accession

0000874015-25-000277

Insider Transaction Report

Form 4

Period: 2025-11-05

IONIS PHARMACEUTICALS INCIONS

Geary Richard S

Senior Vice President

Transactions

Exercise/Conversion
Common Stock
2025-11-05$60.89/sh+801$48,773→ 60,458 total
Sale
Common Stock
2025-11-05$75.01/sh−801$60,083→ 59,657 total
Sale
Common Stock
2025-11-06$76.10/sh−14,738$1,121,521→ 59,657 total
Sale
Common Stock
2025-11-06$75.42/sh−18,300$1,380,204→ 59,657 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-06−14,738→ 0 total
Exercise: $56.78From: 2024-01-04Exp: 2028-01-03→ Common Stock (14,738 underlying)
Exercise/Conversion
Common Stock
2025-11-05$56.78/sh+800$45,424→ 60,457 total
Sale
Common Stock
2025-11-05$75.01/sh−800$60,008→ 59,657 total
Exercise/Conversion
Common Stock
2025-11-06$56.78/sh+14,738$836,824→ 74,395 total
Exercise/Conversion
Common Stock
2025-11-06$60.89/sh+18,300$1,114,287→ 77,957 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-05−800→ 14,738 total
Exercise: $56.78From: 2024-01-04Exp: 2028-01-03→ Common Stock (800 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-05−801→ 18,300 total
Exercise: $60.89From: 2023-01-02Exp: 2027-01-01→ Common Stock (801 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-06−18,300→ 0 total
Exercise: $60.89From: 2023-01-02Exp: 2027-01-01→ Common Stock (18,300 underlying)

Footnotes (4)

[F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.05 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.02 to $75.84 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.84 to $76.65 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT

Issuer

IONIS PHARMACEUTICALS INC

CIK 0000874015

→

Entity typeother

Related Parties

filerCIK 0001442730

Filing Metadata

Form type: 4
Filed: Nov 6, 7:00 PM ET
Accepted: Nov 7, 5:12 PM ET
Size: 24.3 KB

View on SEC.gov